Immunotherapy with the trifunctional anti-CD20 × anti-CD3 antibody FBTA05 in a patient with relapsed t(8;14)-positive post-transplant lymphoproliferative disease

Leuk Lymphoma. 2017 Aug;58(8):1989-1992. doi: 10.1080/10428194.2016.1272687. Epub 2017 Jan 16.

Authors

Anna Kieslich¹, Peter Ruf², Horst Lindhofer², Raynold Buhmann³, Angelika Eggert¹, Patrick Hundsdoerfer¹

Affiliations

¹ a Department of Pediatrics, Division of Oncology and Hematology , Charité University Medicine , Berlin , Germany.
² b TRION Research GmbH , Munich , Germany.
³ c Department of Medicine III and Transfusion Medicine , University Hospital Grosshadern, LMU , Munich , Germany.

PMID: 28093004
DOI: 10.1080/10428194.2016.1272687

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Bispecific / pharmacology
Antibodies, Bispecific / therapeutic use*
Antineoplastic Agents, Immunological / pharmacology
Antineoplastic Agents, Immunological / therapeutic use*
CD3 Complex / antagonists & inhibitors
Child
Chromosomes, Human, Pair 14
Chromosomes, Human, Pair 8
Drug Monitoring
Hematopoietic Stem Cell Transplantation / adverse effects*
Humans
Immunotherapy
Lymphoproliferative Disorders / etiology*
Lymphoproliferative Disorders / mortality
Lymphoproliferative Disorders / pathology
Lymphoproliferative Disorders / therapy*
Male
Neoplasm Staging
Recurrence
Translocation, Genetic*
Treatment Outcome

Substances

Antibodies, Bispecific
Antineoplastic Agents, Immunological
Bi20 antibody
CD3 Complex